Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Notes Payables: 2018-2025

Historic Notes Payables for China SXT Pharmaceuticals (SXTC) over the last 7 years, with Mar 2025 value amounting to $702,184.

  • China SXT Pharmaceuticals' Notes Payables rose 17.93% to $976,367 in Q3 2025 from the same period last year, while for Sep 2025 it was $976,367, marking a year-over-year increase of 17.93%. This contributed to the annual value of $702,184 for FY2025, which is 42.42% up from last year.
  • According to the latest figures from FY2025, China SXT Pharmaceuticals' Notes Payables is $702,184, which was up 42.42% from $493,054 recorded in FY2024.
  • China SXT Pharmaceuticals' 5-year Notes Payables high stood at $702,184 for FY2025, and its period low was $37,122 during FY2021.
  • Moreover, its 3-year median value for Notes Payables was $493,054 (2024), whereas its average is $454,230.
  • Its Notes Payables has fluctuated over the past 5 years, first dropped by 15.44% in 2021, then spiked by 194.44% in 2024.
  • Over the past 4 years, China SXT Pharmaceuticals' Notes Payables (Yearly) stood at $37,122 in 2021, then reached $167,453 in 2023, then spiked by 194.44% to $493,054 in 2024, then soared by 42.42% to $702,184 in 2025.